▌Top Stocks · MEDICAL DEVICES·Updated July 30, 2026
Top Medical Devices Stocks: Our 3 Picks for July 2026
Three medical-device stocks are ranked by investment quality, with women’s health, orthopedics, robotics, and diversified MedTech driving the countdown.
Medical devices remain one of healthcare’s most durable growth themes because demand is tied to procedure volumes, aging demographics, and the continuing shift toward minimally invasive care, outpatient treatment, and connected monitoring. The backdrop favors companies with established commercial products rather than purely speculative technology stories. Installed equipment can support recurring consumables, software, service, and replacement revenue, while new platforms can broaden procedure adoption. Recent developments, including next-generation electrophysiology and surgical technologies, show how product launches can refresh growth even in mature device franchises.
Investors should view the sector in layers. Orthopedic implants and robotics address reconstruction and mobility; cardiovascular and electrophysiology devices target complex, high-value procedures; diagnostics and women’s health support screening and treatment; and hospital infrastructure, infusion, connected care, and patient monitoring enable broader clinical workflows. The strongest businesses typically combine meaningful revenue exposure with scale, regulatory expertise, physician adoption, and products that become embedded in care pathways. Those characteristics can help reduce dependence on any single procedure or hospital-capital cycle.
This countdown ranks three US-listed medical-device names by investment quality, using profitability, growth, valuation, execution, and composite quality measures as the principal guide. Hologic is the women’s-health and diagnostics specialist at No. 3, while Zimmer Biomet brings orthopedic implants and robotic surgery exposure at No. 2. The best-ranked opportunity is reserved for the final section at No. 1.
Our screen was limited to US-listed companies with market capitalizations above $500 million and then ranked the candidates by investment quality. The filter emphasized business durability, operating and net margins, revenue and earnings growth, valuation, recent earnings execution, and analyst consensus. We also considered whether each company has clear exposure to commercially established medical-device categories rather than treating every healthcare company as a device stock. The result is presented in countdown order from No. 3 to No. 1, with the highest-ranked pick revealed last.
What they do. The company develops and supplies diagnostics, medical imaging systems, and surgical products focused on women’s health. Its four segments are Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, with products sold through direct sales and service forces, independent distributors, and sales representatives. The portfolio spans Aptima molecular assays, ThinPrep cytology, 3D mammography, breast-biopsy systems, MyoSure, NovaSure, Fluent, and Horizon DXA, giving Hologic a specialized commercial position across screening, diagnosis, and treatment.
Why it fits. Hologic directly captures several of the medical-devices theme’s most defensible layers: recurring diagnostics, breast-health imaging, and procedure-oriented gynecological surgery. Aptima assays can support repeat testing demand, while mammography and biopsy equipment connect early detection with treatment workflows. MyoSure for uterine fibroids and polyps, NovaSure for abnormal uterine bleeding, and other minimally invasive surgical products give the company exposure to procedure adoption as care increasingly shifts toward less invasive settings.
Numbers that matter. Hologic reported a 60.4% gross margin, a 22.99% operating margin, and a 13.18% net margin, demonstrating meaningful profitability in a specialized device portfolio. Revenue growth was 2.5% year over year, while earnings growth was negative 9.2%, so the current growth profile is more measured than the company’s margin structure. The valuation also sends a mixed signal: trailing P/E was 31.5394 compared with forward P/E of 16.835. That gap implies analysts expect a substantial earnings improvement, with estimated next-year EPS of $3.7786 versus TTM EPS of $2.41.
Recent momentum. Hologic’s supplied earnings history shows a 6/8 beat rate. In the latest reported quarter listed, dated January 29, 2026, EPS was $1.04 versus an estimated $1.10, a 5.5% miss, after four consecutive listed beats from February through November 2025. The analyst panel contains 3 buys and 14 holds, with sells listed as N/A, producing a hold-oriented consensus and an average target of $76.6667. That combination supports Hologic’s quality case but also explains why the stock ranks behind faster-growing alternatives.
What they do. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip implants, sports medicine, biologics, foot and ankle, upper-extremity, trauma, and craniomaxillofacial products. It sells to orthopedic surgeons, hospitals, healthcare institutions, distributors, and purchasing organizations. Zimmer Biomet also offers integrated digital and robotic technologies, including ROSA Robot and the ZBEdge Platform, which connect surgical assistance, data collection, and analytics to the orthopedic care pathway.
Why it fits. Zimmer Biomet is closely aligned with the sector’s aging-demographics and procedure-volume drivers because its core business is joint reconstruction and related orthopedic care. Its robotic and digital tools can strengthen surgeon engagement and support implant positioning, while the broader portfolio spreads exposure across knees, hips, sports medicine, trauma, and foot and ankle procedures. The theme context also notes FDA clearance for ROSA Knee with OptimiZe and the completed Paragon 28 acquisition, developments that deepen the company’s technology and foot-and-ankle exposure.
Numbers that matter. Zimmer Biomet produced $8.4091 billion in revenue, a 70.2% gross margin, a 19.69% operating margin, and a 9.05% net margin. Revenue growth of 9.3% year over year and earnings growth of 34.1% were the strongest growth figures among the three companies in this list. Trailing P/E was 23.8778, while forward P/E was 11.0254, and estimated next-year EPS was $9.0032 compared with TTM EPS of $4.01. The figures point to improving earnings power, although the composite debt-to-equity component received a Strong Sell assessment, making balance-sheet risk an important counterweight.
Recent momentum. Zimmer Biomet’s listed earnings beat rate is 6/7. Its latest completed reported quarter, dated April 28, 2026, delivered EPS of $2.09 versus an estimate of $1.86, a 12.4% positive surprise; the preceding four listed quarters also exceeded estimates. Analysts recorded 6 buys, 16 holds, and 1 sell, with an average target of $99.381. The next listed earnings date is August 5, 2026, with an EPS estimate of $2.01, creating a near-term test for whether recent procedure and execution momentum is holding.
Pick #1Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
The ranking uses primary-source financial data and composite metrics available for each company, with investment quality as the central criterion. We assessed market scale, profitability, return measures, revenue and earnings growth, trailing and forward P/E, earnings-surprise consistency, analyst opinion, and the commercial durability of each medical-device franchise. The universe was restricted to US-listed companies with market capitalizations above $500 million. The list is refreshed monthly, so the ranking can change as financial results, valuations, product developments, analyst views, and quality scores change. Spot prices are intentionally excluded from the evergreen comparison line.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
